摘要
背景:阿尔茨海默病(Alzheimer‘s disease,AD)的病理表现为神经元内神经原纤维缠结,由过度磷酸化的τ和细胞外积累的β淀粉样蛋白(aβ)组成。 方法:采用共聚焦显微镜、光镜、死后对照脑组织和AD患者的脑组织标本进行观察,以SOD 2抗体作为线粒体标记物和抗各种类型τ抗体,通过计算原始整合密度,分析τ阳性神经元线粒体密度和核降解情况。 结果:我们的研究结果显示AD细胞体、营养不良神经突起和神经丝中大量聚集的τ染色,而对照组织中染色较少,而τ阳性神经元的线粒体明显减少。AD的对照神经元或τ阴性神经元线粒体分布均匀,比对照神经元减少40%。对照组与对照组无显着性差异(P>0.05),τ神经元有明显的核降解,且随τ聚集程度的增加而呈进行性变化。聚集的τ浸润并似乎破坏了细胞核的包膜,越来越多的DNA从细胞核中流出,并与聚集的胞内τ结合。 结论:线粒体减少可能是由于蛋白质合成减少所致,而不是由于轴突转运减少而引起的线粒体再分布,提示线粒体减少和核降解是AD神经元丢失的关键机制。
关键词: 线粒体丢失,Sod 2,τ磷酸化,阿尔茨海默病,核降解,蛋白质合成减少
Current Alzheimer Research
Title:Tau Positive Neurons Show Marked Mitochondrial Loss and Nuclear Degradation in Alzheimer's Disease
Volume: 15 Issue: 10
关键词: 线粒体丢失,Sod 2,τ磷酸化,阿尔茨海默病,核降解,蛋白质合成减少
摘要: Background: Alzheimer's disease (AD) pathology consists of intraneuronal neurofibrillary tangles, made of hyperphosphorylated tau and extracellular accumulation of beta amyloid (Aβ) in Aβ plaques. There is an extensive debate as to which pathology initiates and is responsible for cellular loss in AD.
Methods: Using confocal and light microscopy, post mortem brains from control and AD cases, an antibody to SOD2 as a marker for mitochondria and an antibody to all forms of tau, we analyzed mitochondrial density in tau positive neurons along with nuclear degradation by calculating the raw integrative density.
Results: Our findings showed an extensive staining of aggregated tau in cell bodies, dystrophic neurites and neurofilaments in AD with minimal staining in control tissue, along with a marked decrease in mitochondria in tau positive (tau+) neurons. The control or tau negative (tau-) neurons in AD contained an even distribution of mitochondria, which was greatly diminished in tau+ neurons by 40%. There were no significant differences between control and tau- neurons in AD. Tau+ neurons showed marked nuclear degradation which appeared to progress with the extent of tau aggregation. The aggregated tau infiltrated and appeared to break the nuclear envelope with progressively more DNA exiting the nucleus and associating with the aggregated intracellular tau.
Conclusion: We report that the mitochondrial decrease is likely due to a decrease in the protein synthesis rather than a redistribution of mitochondria because of the decreased axonal transport. We suggest that the decrease in mitochondria and nuclear degradation are key mechanisms for the neuronal loss seen in AD.
Export Options
About this article
Cite this article as:
Tau Positive Neurons Show Marked Mitochondrial Loss and Nuclear Degradation in Alzheimer's Disease, Current Alzheimer Research 2018; 15 (10) . https://dx.doi.org/10.2174/1567205015666180613115644
DOI https://dx.doi.org/10.2174/1567205015666180613115644 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Upper Airway Resistance Syndrome
Current Respiratory Medicine Reviews Nicotinamide Supplementation Protects Gestational Diabetic Rats by Reducing Oxidative Stress and Enhancing Immune Responses
Current Medicinal Chemistry Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design The SNPs within 3'UTR of miRNA Target Genes Related to Multiple Sclerosis: A Computational Prediction
Current Pharmacogenomics and Personalized Medicine The Role of IGF-1 Receptor and Insulin Receptor Signaling for the Pathogenesis of Alzheimers Disease: From Model Organisms to Human Disease
Current Alzheimer Research Gene Therapy for the Prevention of Ischemia / Reperfusion Injury in Organ Transplantation
Current Gene Therapy Meet Our Editorial Board Member
Current Alzheimer Research Notoginsenoside R1 Promotes the Growth of Neonatal Rat Cortical Neurons via the Wnt/β-catenin Signaling Pathway
CNS & Neurological Disorders - Drug Targets Alzheimer: A Decade of Drug Design. Why Molecular Topology can be an Extra Edge?
Current Neuropharmacology Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome
Medicinal Chemistry Personalized Medicine: Pharmacogenetics in Psychiatry
Current Pharmacogenomics and Personalized Medicine Epigenetic Changes Associated with Early Life Experiences: Saliva, A Biospecimen for DNA Methylation Signatures
Current Genomics Nanotechnology Based Diagnostic and Therapeutic Strategies for Neuroscience with Special Emphasis on Ischemic Stroke
Current Medicinal Chemistry IL-15 and HIV Infection: Lessons for Immunotherapy and Vaccination
Current HIV Research Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials Re-Balancing of Inflammation and Aβ Immunity as a Therapeutic for Alzheimers Disease-View from the Bedside
CNS & Neurological Disorders - Drug Targets An Efficient Cancer Classification Model for CT/MRI/PET Fused Images
Current Medical Imaging Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry